As HO‐3867 is a versatile antitumour agent with targeting STAT3, PTEN and p53 in various cancer types,22, 23, 24, 25, 26, 27, 28, 29, 30, 31 we attempted to examine whether HO‐3867 suppress OSCC and to analyse how HO‐3867 triggered cell death. The gene discussed is TP53; the disease is cancer.